What question did this study set out to answer?

October 24, 2005CancerOpen Access

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

View Full Paper

Ask AI

Bookmark

Why the study?

Does valsartan reduce acute cardiotoxic changes in humans receiving CHOP chemotherapy?

Population

Humans receiving standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

Authors

HNHirohisa NakamaeOsaka City University KTKei TsumuraShimane University YTYoshiki TeradaSumitomo Dainippon Pharma (Japan)

Discussion

Member takes

Implication

May suggest ARB role in acute CHOP cardiotoxicity; hypothesis-generating and requires randomized confirmation.

Key Points

To evaluate the impact of the angiotensin II receptor blocker valsartan on acute cardiotoxic changes caused by standard CHOP chemotherapy.
Evaluated acute cardiotoxic changes in patients receiving standard CHOP chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Assessed the cardioprotective role of administering the angiotensin II receptor blocker valsartan during treatment.
Indicated that angiotensin II plays an essential role in acute CHOP-induced cardiotoxicity in humans.
Observed notable protective effects of valsartan against acute chemotherapy-induced cardiotoxic changes.

Structured PICO

Does valsartan reduce acute cardiotoxic changes in humans receiving CHOP chemotherapy?

Population

Humans receiving standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)

Intervention

Valsartan

Outcome

Acute cardiotoxic changessafety

Valsartan may mitigate acute cardiotoxicity induced by CHOP chemotherapy, highlighting a potential role for ARBs in cardio-oncology.

Limitations

Does not assess chronic or late-onset types of doxorubicin-induced cardiotoxicity

Cite This Study

Nakamae et al. (2005) studied this question.

synapsesocial.com/papers/69deab2f7702a00918b0c66d https://doi.org/10.1002/cncr.21478

View Full Paper

Ask AI

Bookmark

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider